News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Takeda Pharmaceutical Co. Ltd. (TKPYY)'s DPP-4 Treatment for Type 2 Diabetes Approved in China



8/1/2013 8:05:30 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

July 31, 2013 -- Takeda Pharma, Japan’s largest drugmaker, has been granted CFDA approval for Nesina (alogliptin), a treatment for type 2 diabetes. Nesina is a dipeptidyl peptidase-4 inhibitor (DPP-4). The DPP-4 drugs increase a person’s insulin response and offer both a low-side-effect profile and the convenience of oral administration. More details....

Stock Symbol: (TO: 4502)

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES